Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: The randomized phase III ELOQUENT‐2 study (NCT 01239797) evaluated the efficacy and safety of elotuzumab + lenalidomide/dexamethasone (EL d) versus lenalidomide/dexamethasone (Ld) in relapsed/refractory multiple myeloma. EL d reduced the risk of disease progression/death by 30% versus Ld (hazard ratio [HR] 0·70). Median time from diagnosis was 3·5 years. We present extended 3‐year follow‐up data. Endpoints included progression‐free survival (PFS), overall response rate (ORR) and interim overall survival (OS). Exploratory post‐hoc analyses included impact of time from diagnosis and prior lines of therapy on PFS, and serum M‐protein dynamic modelling. ORR was 79% (EL d) and 66% (Ld) (P = 0·0002). EL d reduced the risk of disease progression/death by 27% versus Ld (HR 0·73; P = 0·0014). Interim OS demonstrated a trend in favour of EL d (P = 0·0257); 1‐, 2‐ and 3‐year rates with EL d versus Ld were: 91% versus 83%, 73% versus 69% and 60% versus 53%. In patients with ≥ median time from diagnosis and one prior therapy, EL d resulted in a 53% reduction in the risk of progression/death versus Ld (HR 0·47). Serum M‐protein dynamic modelling showed slower tumour regrowth with EL d. Adverse events were comparable between arms. EL d provided a durable and clinically relevant improvement in efficacy, with minimal incremental toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Self-citationCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Self-citation
Research works printed but not linked: 5
- 10.1007/s00262-013-1493-8 · DOI · Paper page
- 10.1038/leu.2009.147 · DOI · Paper page
- 10.1158/1078-0432.CCR-07-4246 · DOI · Paper page
- 10.1038/clpt.2009.64 · DOI · Paper page
- 10.1158/1078-0432.CCR-09-1624 · DOI · Paper page
Cited by
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Dimopoulos, M. A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X., LeBlanc, R., Suzuki, K., Raab, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805762 · Cited by 535
Self-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Multiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 355
Metadata
- Authors
- Dimopoulos, M. A., Lonial, S., White, D., Moreau, P., Palumbo, A., San‐Miguel, J., Shpilberg, O., Anderson, K., Grosicki, S., Spicka, I., Walter‐Croneck, A., Magen, H., Mateos, M., Belch, A., Reece, D., Beksac, M., Bleickardt, E., Poulart, V., Sheng, J., Sy, O., Katz, J., Singhal, A., & Richardson, P.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2017-07-05
- Volume
- 178
- Issue
- 6
- Pages
- 896-905
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2732548543
- Cited by
- 135
- References
- 4
- FWCI
- 15.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Bristol-Myers Squibb in collaboration with AbbVie Biotherapeutics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.